Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Richeek Pradhan"'
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 11, Iss 6 (2023)
Introduction The dipeptidyl peptidase-4 (DPP-4) enzyme significantly influences carcinogenic pathways in the skin. The objective of this study was to determine whether DPP-4 inhibitors are associated with the incidence of melanoma and nonmelanoma ski
Externí odkaz:
https://doaj.org/article/d150709e9daf4b6dab03469f660afeaf
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 15, Iss 1 (2022)
Background and objectives India, the country with the largest market availability of antimicrobial fixed-dose combinations (FDCs), banned certain antimicrobial FDCs in September 2018. Our objective was to examine the impact of Government ban on the s
Externí odkaz:
https://doaj.org/article/a1cd68ed9b4f48a0b4010c37937d880c
Autor:
Richeek Pradhan, Olivia Bonardi
Publikováno v:
McGill Journal of Medicine, Vol 17, Iss 1 (2020)
Transparency in clinical trials is an issue under considerable scrutiny at present, and rightfully so, given that people's lives are both used as a resource in such research and affected by its results. Hence, the results of clinical trials conducted
Externí odkaz:
https://doaj.org/article/4486dc3c633d4cb7b796c0de261c03d3
Autor:
Supriyo Choudhury, Richeek Pradhan, Lily Dubey, Lisa Barman, Tanmoy Biswas, Manisha Das, Suparna Chatterjee
Publikováno v:
Perspectives in Clinical Research, Vol 7, Iss 2, Pp 94-99 (2016)
Aims: By virtue of being a specialized field by itself, the science of clinical trials (CTs) may not be well understood by doctors who are not specifically trained in it. A lack of knowledge may translate to a negative perception toward CT. With the
Externí odkaz:
https://doaj.org/article/10f0a6904bf14a17b8f43e7be38819f4
Autor:
Raghavendra Charan P Makam, David C Hoaglin, David D McManus, Victoria Wang, Joel M Gore, Frederick A Spencer, Richeek Pradhan, Hoang Tran, Hong Yu, Robert J Goldberg
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0197583 (2018)
BACKGROUND:Direct oral anticoagulants (DOACs) have emerged as promising alternatives to vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE). Few meta-analyses have included all DOACs
Externí odkaz:
https://doaj.org/article/056d389410bf4bad84f27296ed54b45e
Autor:
Richeek Pradhan, Soumita De, Nidhi Choudhary, Shibabrata Mukherjee, Gobinda Chatterjee, Arghyaprasun Ghosh, Mitali Chatterjee, Suparna Chatterjee
Publikováno v:
Indian Journal of Dermatology, Vol 59, Iss 6, Pp 547-551 (2014)
Background: Generalized vitiligo is a disease with unpredictable bursts of activity, goal of treatment during the active phase being to stabilize the lesions. This emphasizes the need for a prospective marker for monitoring disease activity to help d
Externí odkaz:
https://doaj.org/article/1b137c0ad11d4077a524d649939f569a
Autor:
Sudip Chatterjee, Richeek Pradhan
Publikováno v:
Trials, Vol 18, Iss 1, Pp 1-2 (2017)
Abstract Arch and colleagues in their 24 October 2016 paper in Trials focus on the issue of centralised versus local measurement of glycated haemoglobin (HbA1c) in clinical trial settings. Resolution of the debate is important: while local HbA1c meas
Externí odkaz:
https://doaj.org/article/6d9dfaa4b4764024bac06f740991d6dc
Autor:
Richeek, Pradhan, Elisabetta, Patorno, Helen, Tesfaye, Sebastian, Schneeweiss, Hui, Yin, Jessica, Franklin, Ajinkya, Pawar, Christina, Santella, Oriana H Y, Yu, Christel, Renoux, Laurent, Azoulay
Publikováno v:
Am J Epidemiol
Case reports and a pharmacovigilance analysis have linked glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with anaphylactic reactions, but real-world evidence for this possible association is lacking. Using databases from the United Kingdom (Cl
Publikováno v:
Diabetes Care. 45:819-829
OBJECTIVE To determine whether glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter 2 (SGLT-2) inhibitors, separately, are associated with a decreased risk of nonalcoholic fatty liver disease (NAFLD) compared with d
Autor:
Richeek Pradhan, Sally Lu, Hui Yin, Oriana H Y Yu, Pierre Ernst, Samy Suissa, Laurent Azoulay
Publikováno v:
BMJ (Clinical research ed.). 379
Objective To determine whether the use of glucagon-like peptide 1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, separately, is associated with a decreased risk of exacer